Integrative treatment of autism and intractable brain diseases to make me, family and society happy

22-10-11

“Possession of pipeline materials and research for brain development disorders/intractable brain diseases ahead of advanced countries”

Since 2013, autism, Asperger's, and other developmental disorders have been collectively classified as autism spectrum disorder according to the International Classification of Diseases, according to the diagnostic criteria DSM-5. From autism to autism, the area of 'autism' is diverse. Cognition and communication problems, coexisting symptoms such as anxiety and seizures, and stereotyped behavior make it impossible to live without the help of a guardian, and the pathogenesis of this disorder has not been clearly identified. In addition, social interest in brain development disorders such as ADHD (Attention Deficit Hyperactivity) has increased and some treatments have been developed, but there is still an unmet medical need and there is a very high demand for new treatments for some developmental disorders. Despite this situation, there is no successful case beyond the 3rd clinical trial for autism spectrum disorder in the field of international medicine. It shows the potential and possibility of K medicine.

Brain-related new drug development and treatment platform development in progress according to 4 pipelines

There is no suitable treatment for autism spectrum disorder, which affects 1 in 50 Koreans, suffers from both patients and guardians, and the market for behavioral cognitive psychotherapy alone reaches 6 trillion won. R&D investment is relatively small due to the high risk both at home and abroad, but CEO Shin Chan-young, a professor at Konkuk University Graduate School of Medicine, who is one of the first generation in the field of basic research on autism in Korea, runs the startup support program TIPS of the Ministry of SMEs and Startups. Founded Neuroventi and its affiliated research institute. CEO Shin challenged the treatment of autism spectrum disorder and intractable brain disease, the only CNS disease (cerebral nerve disease) for which there is no cure, and produced an animal research model, published the first basic research paper related to autism developmental disorder in Korea, and ranked in the top 1% of citations. have been shown In addition, through Neuroventi Co., Ltd., it has established complex target precision control technology that is effective for intractable brain diseases such as autism, depression, schizophrenia, and Parkinson's disease, which are developmental disabilities, and is starting a new drug development project and preparing for clinical trials. In addition, it is playing a role as a technical solver for other brain disease treatment development companies through CRO research agency services and non-clinical test CDRO services that evaluate the efficacy and central nervous system side effects of candidates made by brain disease treatment companies. Neuroventi Co., Ltd., composed of 6 Ph.D. degree holders in bio and pharmaceutical sciences and 4 master's degree R&D personnel, has 4 excellent pipelines based on research achievements so far, each with autism-related gene signaling control and multiple neurotransmission. Clinical trials are being conducted/scheduled on topics such as substances, social sex hormones, and neuromodulation by trigeminal nerve stimulation. Currently, 'NV01-A02', which deals with ASD (autism spectrum disorder) and FXS (fragile X syndrome), and 'NV01-A03', which deals with ASD, are in the clinical preparation stage, and 'NV01-E01', which deals with ASD, in the field of electroceuticals ' was approved for the second clinical trial (medical device exploration clinical trial). 'NV01-062' is a new small molecule chemical, and non-clinical trials related to ASD are underway.

Green light for clinical trial results by discovery of complex target regulation mechanism of autism spectrum disorder

In the process of taking more than 5 years to be used as a treatment, the degree of toxicity must be confirmed in animal experiments (non-clinical) and recognized in phase 1-3 clinical trials, and CEO Shin has achievements at least 1-2 years ahead of advanced countries. He holds a number of patents related to autism-developmental disorders and intractable brain diseases, and plans to enter phase 2 clinical trials for patients next year. It is explained by the 'air balloon (balloon) hypothesis'. This hypothesizes that in order to maintain normal brain function by contrasting the principle of the balloon rising and sinking with excitation and inhibition mechanisms, it is necessary to be able to control the balloon so that it does not sink or float too much. One of the representative research achievements of CEO Shin is that he entered into a non-clinical experiment on the complex target control mechanism. The reason why Neuroventi Co., Ltd. is unique comes from this. Among the dozens of neurotransmission control mechanisms that directly act on the brain, it is necessary to find out some of the most important ones and to make such complex target control possible in practice to expand and use it for most patients. because it can In addition, since it understands the key mechanisms of controlling major autism symptoms and has candidate substances that can be controlled at the same time, Neuroventi expects to reach the development of new drugs related to autism spectrum disorder faster than anywhere else in the world when clinical trials are successful. Domestic autism research is more than 15 years behind Alzheimer's, which has a 30-year tradition. Nevertheless, thanks to this complex target modifier, Neuroventi Co., Ltd. is developing protein structure prediction design technology using AI-emerging technology as well as biological/medical/pharmaceutical fields. We were able to proceed with practical technology commercialization through industry-university MOUs with adjacent technology-holding institutions related to the treatment of brain development disorders, including As of 2022, CEO Shin has signed MOUs with Wooridul Pharmaceutical, Pharmcad, New Ain, and Abio Materials, adding that more partners will be added in the future.

The ultimate goal is ‘Brain well-being’ through the development of ‘First-in-Disease’ medicines

During the period of 5-10 years of receiving approval for manufacturing and selling new drug candidates using drug structure design, CEO Shin commercialized the 'NV01-E01' pipeline, an electronic medicine field that stimulates the brain nerve with light electricity, in addition to new drugs related to brain development disorders. , and collaboration with companies specializing in digital game/VR behavioral education and treatment candidate products. As a way that several global companies, including Takeda, are proceeding overseas, CEO Shin is also envisioning a three-type complex treatment of drugs, electronic medicines, and digital therapeutics. In addition, the population of autism spectrum disorder exceeds 2.5% of the total population (2.64% in Korea), and compared to Alzheimer's, which Korea evaluates as having a research level equivalent to that of the United States, Korea is also more likely to improve social awareness of this disease and the government It adds that support needs to be expanded. Among the autism spectrum disorder population, there are cases where socialization was achieved through the efforts of parents, but unfortunately there are quite a few patients with severe symptoms who cannot even express their opinions, so CEO Shin succeeded in clinical trials, and children aged 3 to 5 were diagnosed and managed with medicine to normalize I really hope that he catches up with his developmental trajectory and shows signs of improvement. “The best way to be able to live a normal school life with complete resolution, the second line to be able to maintain a normal life by taking medication consistently, and the second line to improve even severe symptoms so that education and employment are possible to some extent are successful. ' and their families will be happy, and our society will be able to embrace autistic people and live together,” said CEO Shin. It is said that it will change the history of medicine by leading good treatment drugs for brain diseases. In addition, CEO Shin will be reborn as the first bio-venture company that will solve patients' symptoms with a combination prescription of drugs and electronic medicines and create a society that respects and understands each other and achieves individual interactions by utilizing high-level brain functions. announced that it will become a bio company that expands into various public projects such as educational program research, job placement and direct employment, and will become a company that realizes 'brain well-being'.